Cargando…

PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis

BACKGROUND: Ovarian “seromucinous carcinoma” has been recently removed in 2020 5(th) Edition of WHO classification of Female Genital Tumors and is considered as a subtype of endometrioid carcinoma with mucinous differentiation, while “seromucinous borderline tumor” remains and exists as a distinct e...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Bo Seong, Won, Seyeon, Kim, Ju-Hyun, Lee, Nara, Kim, Miseon, Kim, Mi Kyoung, Kim, Mi-La, Jung, Yong Wook, Kim, Ji Young, Seong, Seok Ju, Shin, Eunah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985320/
https://www.ncbi.nlm.nih.gov/pubmed/35387670
http://dx.doi.org/10.1186/s13048-022-00975-5
_version_ 1784682342736986112
author Yun, Bo Seong
Won, Seyeon
Kim, Ju-Hyun
Lee, Nara
Kim, Miseon
Kim, Mi Kyoung
Kim, Mi-La
Jung, Yong Wook
Kim, Ji Young
Seong, Seok Ju
Shin, Eunah
author_facet Yun, Bo Seong
Won, Seyeon
Kim, Ju-Hyun
Lee, Nara
Kim, Miseon
Kim, Mi Kyoung
Kim, Mi-La
Jung, Yong Wook
Kim, Ji Young
Seong, Seok Ju
Shin, Eunah
author_sort Yun, Bo Seong
collection PubMed
description BACKGROUND: Ovarian “seromucinous carcinoma” has been recently removed in 2020 5(th) Edition of WHO classification of Female Genital Tumors and is considered as a subtype of endometrioid carcinoma with mucinous differentiation, while “seromucinous borderline tumor” remains and exists as a distinct entity. Both diseases may be considered as no more same lineage. However, ovarian seromucinous borderline tumor (SMBT) is also one of the endometriosis-related neoplasm of ovary similar to endometrioid tumor, featuring that about 50% of ovarian SMBTs combine endometriosis. The present study was aimed to investigate whether the ovarian SMBTs are different in clinical features and molecular patterns, according to the presence of combined endometriosis. RESULTS: There were no statistical differences in clinical findings between two groups. There was also no significant difference in pregnancy outcomes and recurrence between two groups. In immunohistochemical patterns, there was a statistically significant difference in PAX2 and PAX8 expression between in ovarian SMBT with or without endometriosis (P = 0.016, P < 0.001). Only a few cases of ovarian SMBT with endometriosis showed expression of PAX2 and conversely, most of the cases showed expression of PAX8. PR positivity was more prominent in ovarian SMBT with endometriosis than without endometriosis (P = 0.018), although there was no difference in positive ER expression. There were no statistical differences in WT1, CK20 and CDX2 expressions between two groups. CONCLUSIONS: Ovarian SMBT with endometriosis did not clinically differ from that without endometriosis. However, the molecular patterns were different between two groups and ovarian SMBT with endometriosis is close to endometrioid tumor types unlike SMBT without endometriosis. Further, a direct comparison study between seromucinous borderline tumor and endometrioid borderline tumor is needed with a gene profiling study to prove their relationship.
format Online
Article
Text
id pubmed-8985320
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89853202022-04-07 PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis Yun, Bo Seong Won, Seyeon Kim, Ju-Hyun Lee, Nara Kim, Miseon Kim, Mi Kyoung Kim, Mi-La Jung, Yong Wook Kim, Ji Young Seong, Seok Ju Shin, Eunah J Ovarian Res Research BACKGROUND: Ovarian “seromucinous carcinoma” has been recently removed in 2020 5(th) Edition of WHO classification of Female Genital Tumors and is considered as a subtype of endometrioid carcinoma with mucinous differentiation, while “seromucinous borderline tumor” remains and exists as a distinct entity. Both diseases may be considered as no more same lineage. However, ovarian seromucinous borderline tumor (SMBT) is also one of the endometriosis-related neoplasm of ovary similar to endometrioid tumor, featuring that about 50% of ovarian SMBTs combine endometriosis. The present study was aimed to investigate whether the ovarian SMBTs are different in clinical features and molecular patterns, according to the presence of combined endometriosis. RESULTS: There were no statistical differences in clinical findings between two groups. There was also no significant difference in pregnancy outcomes and recurrence between two groups. In immunohistochemical patterns, there was a statistically significant difference in PAX2 and PAX8 expression between in ovarian SMBT with or without endometriosis (P = 0.016, P < 0.001). Only a few cases of ovarian SMBT with endometriosis showed expression of PAX2 and conversely, most of the cases showed expression of PAX8. PR positivity was more prominent in ovarian SMBT with endometriosis than without endometriosis (P = 0.018), although there was no difference in positive ER expression. There were no statistical differences in WT1, CK20 and CDX2 expressions between two groups. CONCLUSIONS: Ovarian SMBT with endometriosis did not clinically differ from that without endometriosis. However, the molecular patterns were different between two groups and ovarian SMBT with endometriosis is close to endometrioid tumor types unlike SMBT without endometriosis. Further, a direct comparison study between seromucinous borderline tumor and endometrioid borderline tumor is needed with a gene profiling study to prove their relationship. BioMed Central 2022-04-06 /pmc/articles/PMC8985320/ /pubmed/35387670 http://dx.doi.org/10.1186/s13048-022-00975-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yun, Bo Seong
Won, Seyeon
Kim, Ju-Hyun
Lee, Nara
Kim, Miseon
Kim, Mi Kyoung
Kim, Mi-La
Jung, Yong Wook
Kim, Ji Young
Seong, Seok Ju
Shin, Eunah
PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis
title PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis
title_full PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis
title_fullStr PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis
title_full_unstemmed PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis
title_short PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis
title_sort pax2, pax8, and pr are correlated with ovarian seromucinous borderline tumor with endometriosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985320/
https://www.ncbi.nlm.nih.gov/pubmed/35387670
http://dx.doi.org/10.1186/s13048-022-00975-5
work_keys_str_mv AT yunboseong pax2pax8andprarecorrelatedwithovarianseromucinousborderlinetumorwithendometriosis
AT wonseyeon pax2pax8andprarecorrelatedwithovarianseromucinousborderlinetumorwithendometriosis
AT kimjuhyun pax2pax8andprarecorrelatedwithovarianseromucinousborderlinetumorwithendometriosis
AT leenara pax2pax8andprarecorrelatedwithovarianseromucinousborderlinetumorwithendometriosis
AT kimmiseon pax2pax8andprarecorrelatedwithovarianseromucinousborderlinetumorwithendometriosis
AT kimmikyoung pax2pax8andprarecorrelatedwithovarianseromucinousborderlinetumorwithendometriosis
AT kimmila pax2pax8andprarecorrelatedwithovarianseromucinousborderlinetumorwithendometriosis
AT jungyongwook pax2pax8andprarecorrelatedwithovarianseromucinousborderlinetumorwithendometriosis
AT kimjiyoung pax2pax8andprarecorrelatedwithovarianseromucinousborderlinetumorwithendometriosis
AT seongseokju pax2pax8andprarecorrelatedwithovarianseromucinousborderlinetumorwithendometriosis
AT shineunah pax2pax8andprarecorrelatedwithovarianseromucinousborderlinetumorwithendometriosis